Clinical and histopathological features and a unique spectrum of organisms significantly associated with chronic granulomatous disease osteomyelitis during childhood

Clinical Infectious Diseases

Volumn 46, Issue 5, 2008, Pages 745-749

  Galluzzo, M L ^a   Hernandez, C ^a   Davila, M T G ^a   Perez L ^a   Oleastro, M ^a   Zelazko, M ^a   Rosenzweig, Sergio D ^a  

^a HOSPITAL DE PEDIATRÍA PROF DR JUAN P GARRAHAN   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT;

ALPHA HEMOLYTIC STREPTOCOCCUS; ANALYTIC METHOD; ARTICLE; CHILD; CHRONIC GRANULOMATOUS DISEASE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; ENTEROBACTER; ESCHERICHIA COLI; HISTOPATHOLOGY; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIOLOGICAL EXAMINATION; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; OSTEOMYELITIS; PRIORITY JOURNAL; PROPHYLAXIS; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS EPIDERMIDIS; ASPERGILLOSIS; ASPERGILLUS; BONE; CASE CONTROL STUDY; CHEMOPROPHYLAXIS; ENTEROBACTER INFECTION; INFANT; ISOLATION AND PURIFICATION; MICROBIOLOGY; MYCOSIS; PATHOLOGY; PATHOPHYSIOLOGY; PENICILLIUM; PRESCHOOL CHILD; SERRATIA MARCESCENS;

ANTI-BACTERIAL AGENTS; ASPERGILLOSIS; ASPERGILLUS; BONE AND BONES; CASE-CONTROL STUDIES; CHEMOPREVENTION; CHILD; CHILD, PRESCHOOL; GRANULOMATOUS DISEASE, CHRONIC; HUMANS; INFANT; MYCOSES; OSTEOMYELITIS; PENICILLIUM; SERRATIA INFECTIONS; SERRATIA MARCESCENS;

EID: 39749110055     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/527446     Document Type: Article

References (22)

1. Segal BH, Leto TL, Gallin JI, Malech HL, Holland SM. Genetic, biochemical, and clinical features of chronic granulomatous disease. Medicine (Baltimore) 2000; 79:170-200.
2. Winkelstein, JA, Marino, MC, Johnston RB Jr, et al. Chronic granulomatous disease: report on a national registry of 368 patients. Medicine (Baltimore) 2000; 79:155-69.
3. Margolis DM, Melnick DA, Alling DW, Gallin JI. Trimethoprim- sulfamethoxazole prophylaxis in the management of chronic granulomatous disease. J Infect Dis 1990; 162:723-6.
4. The International Chronic Granulomatous Disease Cooperative Study Group. A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. N Engl J Med 1991; 324:509-16.
5. Gallin JI, Alling DW, Malech HL, et al. Itraconazole to prevent fungal infections in chronic granulomatous disease. N Engl J Med 2003; 248:2416-22.
6. Marciano BE, Rosenzweig SD, Kleiner DE, et al. Gastrointestinal involvement in chronic granulomatous disease. Pediatrics 2004; 114:462-8.
7. Walther MM, Malech HL, Berman A, et al. The urologic manifestations of chronic granulomatous disease. J Urol 2002; 147:1314-8.
8. Goldblatt D, Butcher J, Thrasher AJ, Russell-Eggitt I. Chorioretinal lesions in patients and carriers of chronic granulomatous disease. J Pediatr 1999; 134:780-3.
9. Brandrup F, Koch C, Petri M, Schiodt M, Johansen KS. Discoid lupus erythematosus-like lesions and stomatitis in female carriers of X-linked chronic granulomatous disease. Br J Dermatol 1981; 104:495-505.
10. De Ravin SS, Naumann N, Robinson MR, et al. Sarcoidosis in chronic granulomatous disease. Pediatrics 2006; 117:590-5.
11. Cotram RS, Kumar V, Collins T. Acute and chronic inflammation. In: Cotram RS, Kumar V, Collins T, eds. Robbins, pathologic basis of disease, 6th ed. Philadelphia: WB Saunders, 1999:50-88.
12. Santos PE, Piontelli E, Shea YR, et al. Penicillium piceum infection: diagnosis and successful treatment in chronic granulomatous disease. Med Mycol 2006; 44:749-53.
13. Liese J, Kloos S, Jendrossek V, et al. Long-term follow-up and outcome of 39 patients with chronic granulomatous disease. J Pediatr 2000; 137:687-93.
14. Soler-Palacín P, Margareto C, Llobet P, et al. Chronic granulomatous disease in pediatric patients: 25 years of experience. Allergol Immunopathol 2007; 35:83-9.
15. Movahedi M, Aghamohammadi A, Rezaei N, et al. Chronic granulomatous disease: a clinical survey of 41 patients from the Iranian primary immunodeficiency registry. Int Arch Allergy Immunol 2004; 134:253-9.
16. Study Group of Phagocyte Disorders of Japan and Masafumi Hasai. Chronic granulomatous disease in Japan: incidence and natural history. Pediatr Int 1999; 41:589-93.
17. Segal BH, DeCarlo ES, Kwon-Chung KJ, Malech HL, Gallin JI, Holland SM. Aspergillus nidulans infection in chronic granulomatous disease. Medicine (Baltimore) 1998; 77:345-54.
18. Waites KB, Duffy LB, Dowzicky MJ. Antimicrobial susceptibility among pathogens collected from hospitalized patients in the United States and in vitro activity of tigecycline, a new glycylcycline antimicrobial. Antimicrob Agents Chemother 2006; 50:3479-84.
19. Means RT. Advances in the anemia of chronic disease. Int J Hematol 1999; 70:7-12.
20. Brown JR, Goldblatt D, Buddle J, Morton L, Thrasher AJ. Diminished production of anti-inflammatory mediators during neutrophil apoptosis and macrophage phagocytosis in chronic granulomatous disease (CGD). J Leukoc Biol 2003; 73:591-9.
21. Levine S, Smith VV, Malone M, Sebire NJ. Histopathological features of chronic granulomatous disease (CGD) in childhood. Histopathology 2005; 47:508-16.
22. Kobayashi SD, Voyich JM, Braughton KR, et al. Gene expression profiling provides insight into the pathophysiology of chronic granulomatous disease. J Immunol 2004; 172:636-43.